132465-11-3

132465-11-3 structure

Name: Cinnamyl-3,4-dihydroxy-α-cyanocinnamate
Chemical Name: cdc
CAS Number: 132465-11-3
Molecular Formula: C₁₉H₁₅NO₄
Molecular Weight: 321.32700
Catalog: Signaling Pathways Metabolic Enzyme/Protease 5-Lipoxygenase
Create Date: 2018-12-02 10:19:07
Modify Date: 2024-01-16 18:03:34
Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus[1].

Name	cdc

Description	Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> 5-Lipoxygenase Research Areas >> Metabolic Disease
In Vitro	High glucose or 12(S)-HETE remarkably increased transendothelial dextran transport, and in combination it was increased further. Addition of the 12/15-LO inhibitor, CDC, partially suppressed dextran transport[1].
In Vivo	The high glucose and 12(S)-hydroxyeicosatetraenoic acid (HETE) could alter vascular endothelial (VE)-cadherin and β‐catenin phosphorylation levels, but did not alter total protein expression. However, the 12/15-LO inhibitor, Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC), antagonized the effect of high glucose on protein phosphorylation to mitigate destruction of the endothelial cell barrier, and the mouse diabetes mellitus model further confirmed these conclusions[1].
References	[1]. Wang X, et al. 12(S)-hydroxyeicosatetraenoic acid impairs vascular endothelial permeability by altering adherens junction phosphorylation levels and affecting the binding and dissociation of its components in high glucose-induced vascular injury. J Diabetes Investig. 2019;10(3):639-649.

Precursor 1
139-85-5
DownStream 0